liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Health-Related Quality of Life In Patients With Adrenal Insufficiency Receiving Plenadren Compared With Immediate-Release Hydrocortisone.
Sahlgrenska University Hospital, Gothenburg, Sweden.
Sahlgrenska University Hospital, Gothenburg, Sweden.
Shire, Danderyd, Sweden.
Östergötlands Läns Landsting, Heart and Medicine Center, Department of Endocrinology. Linköping University, Department of Medical and Health Sciences, Division of Cardiovascular Medicine. Linköping University, Faculty of Medicine and Health Sciences.
Show others and affiliations
2015 (English)In: Value in Health, ISSN 1098-3015, E-ISSN 1524-4733, Vol. 18, no 7, A616- p.Article in journal, Meeting abstract (Refereed) Published
Abstract [en]

Background

Previous studies in patients with primary adrenal insufficiency (PAI) on conventional replacement therapy suggest decreased health-related quality of life (HRQoL), and that patients report more frequently fatigue, increased anxiety and inability to work compared to background population.

Objectives

To study self-reported health status with EQ-5D in patients with PAI. Patients treated with Plenadren (modified-release hydrocortisone) were compared with patients treated with immediate release hydrocortisone (IRHC) replacement therapy.

Methods

This was a cross-sectional, multi-centre, non-interventional survey of patients with PAI receiving Plenadren or immediate release hydrocortisone (IRHC) replacement.

Subjects

One hundred thirty-four adult patients with PAI of whom 36 (19 females [53%]) were treated with Plenadren and 98 (77 females [79%]) were treated with IRHC, were included.

MAIN OUTCOME MEASURE

HRQoL described by the EQ-5D, a generic preference-based measure of health.

RESULTS

Patients on Plenadren and on IRHC had a mean ± SD age of 53.1 ± 12.7 years and 48.0 ± 13.1 years, respectively (P=0.043). The majority of the patients were diagnosed more than 5 years ago (69%). The mean ± SD daily Plenadren and IRHC doses were 27.0 ± 6.8 mg and 26.6 ± 10.9 mg, respectively (P=0.807). 47% of the Plenadren patients had been receiving Plenadren and 82% of the IRHC patients had been receiving IRHC for more than 3 years. Patients receiving Plenadren had better HRQoL measured by the EQ-5D questionnaire compared to patients replaced with IRHC (0.76 ± 0.18 vs 0.68 ± 0.18, respectively [P=0.040]).

CONCLUSIONS

Replacement therapy with Plenadren in patients with PAI confers measurable benefit on HRQoL relative to IRHC as estimated by the EQ-5D questionnaire, and may therefore be advantageous when compared to IRHC substitution.

Place, publisher, year, edition, pages
2015. Vol. 18, no 7, A616- p.
National Category
Health Care Service and Management, Health Policy and Services and Health Economy Surgery
Identifiers
URN: urn:nbn:se:liu:diva-124656DOI: 10.1016/j.jval.2015.09.2145PubMedID: 26533455OAI: oai:DiVA.org:liu-124656DiVA: diva2:901830
Available from: 2016-02-09 Created: 2016-02-08 Last updated: 2016-04-12

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Ekman, BertilWahlberg, Jeanette
By organisation
Department of EndocrinologyDivision of Cardiovascular MedicineFaculty of Medicine and Health Sciences
In the same journal
Value in Health
Health Care Service and Management, Health Policy and Services and Health EconomySurgery

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 241 hits
ReferencesLink to record
Permanent link

Direct link